But a challenge to an Orange Book patent, should a brand-name manufacturer decide to fight in court, also delays a generic’s approval for 30 months. The FTC says that drugmakers needlessly list ...
What Happened: The FTC is disputing “junk patent listings” for diabetes, weight loss, asthma and COPD drugs. This initiative represents the latest endeavor against what the agency perceives as ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk ... on," FTC Chair Lina Khan said. The agency sent letters to 10 companies, warning that their patent listings were ...
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining ... they rely on,” FTC Chair Lina Khan ...
FTC’s latest action targets more than 300 Orange Book patent listings across 10 different companies, which brings the total to more than 400 patent listings across 14 companies and should send a ...
Most recently, on April 30, 2024, the FTC initiated a second round of patent listing disputes – this one targeting more than 300 device patent listings for 20 medicines approved to treat ...
The US Federal Trade Commission (FTC) has expanded its campaign against so-called ‘junk’ patents intended ... disputing more than 300 patent listings in its Orange Book covering 20 brands ...
The US Federal Trade Commission (FTC) revealed on Friday that it has filed an amicus brief explaining that pharmaceutical maker Teva Pharmaceutical Industries (NYSE: TEVA) has improperly listed ...